This morning, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) witnessed a remarkable surge in stock price, soaring by 60.59% to $6.52, following the announcement of promising clinical study outcomes.
Innovative NanoAb Treatment Targets Mild to Moderate Plaque Psoriasis
Scinai revealed successful in-vivo preclinical study results of its groundbreaking anti IL-17A/F VHH antibody fragment, branded as ‘NanoAb’. This innovative treatment represents a pioneering intralesional biological approach tailored for the large and underserved population suffering from mild to moderate plaque psoriasis.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Scinai’s NanoAb is engineered to address the significant limitations of current therapies by delivering targeted treatment directly into psoriatic lesions using a minimally invasive, nearly painless injection method. Unlike traditional corticosteroids or systemic biologics, Scinai’s biologic offers high specificity and potency with markedly reduced risks of local and systemic side effects.
Clinical Development
Led by Prof. Amos Gilhar of the Technion, Israel Institute of Technology, Haifa, the study demonstrated NanoAb’s efficacy in reducing both IL-17A and IL-17F isoforms within psoriatic skin tissue, showcasing its potential as a superior alternative to existing treatments.
Human skin was transplanted into the backs of SCID-Beige mice, and psoriasis was created by administering activated human peripheral blood mononuclear cells (PBMCs) from psoriasis patients.
This disease-induced skin model replicates essential aspects of plaque psoriasis tissue architecture and the cytokine profile associated with the inflammatory state of plaque psoriasis lesions. The mice were separated into research groups, and each group was treated for two weeks. The therapeutic efficacy was then assessed for three further weeks following the last therapy.
Future Steps
These encouraging findings pave the way for Scinai’s continued development efforts. The company plans to refine dosing and drug half-life parameters while preparing for a comprehensive in-vivo animal study in late 2024. This will be followed by a pre-clinical toxicology assessment, setting the stage for a first-in-human clinical trial anticipated to commence in late 2025.
Scinai’s commitment to advancing specific, effective, and safe biologic treatments for plaque psoriasis signifies a significant advancement in addressing the unmet needs of mild to moderate psoriatic patients worldwide.
